Avid Bioservices, Inc.
NASDAQ Capital Market•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.Company Description
- CEO
- Nicholas Stewart Green MBA
- Full Time Employees
- 371
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 2642 Michelle Drive Tustin CA United States of America 92780
- IPO Date
- Apr 4, 1994
- CIK
- 0000704562
- Website
- avidbio.com
- Similar Companies
- Business
- Avid Bioservices, Inc., a contract development and manufacturing organization, provides process development and current good manufacturing practices (CGMP) clinical and commercial manufacturing services focused on biopharmaceutical drug substances derived from mammalian cell culture. The company produces monoclonal antibodies and recombinant proteins; and offers services, including CGMP clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing, and regulatory submission and support. It also provides various process development services, such as upstream and downstream development and optimization, analytical methods development, testing, and characterization. The company serves biotechnology and biopharmaceutical industries. The company was formerly known as Peregrine Pharmaceuticals, Inc. and changed its name to Avid Bioservices, Inc. in January 2018. Avid Bioservices, Inc. was incorporated in 1981 and is headquartered in Tustin, California.
Company News
Tufts Center Study Shows Significant Time Savings in Delivering Therapies to Patients with Thermo Fisher Scientific's Accelerator™ Drug Development 360° CDMO and CRO Solutions
Scinai Highlights New Funding and CDMO Growth Ahead of BIO International Convention 2025
Frédéric Robert appointed EUROAPI's Chief Commercial Officer overseeing API Solutions and CDMO activities
Scinai Reports Q1 2025 Financial Results Highlighting Strong CDMO Revenue Momentum and Reduced Cash Burn
BioHarvest Secures New CDMO Contract to Develop Plant-based Fragrance Compound
BioHarvest Sciences advances CDMO deal with major pharmaceutical company - ICYMI
BioHarvest Sciences advances CDMO project with Nasdaq-listed pharmaceutical company to next stage
BioHarvest Announces Completion of Stage 1 Development for CDMO Contract with Nasdaq-Listed Pharmaceutical Company
Lifecore Biomedical to Participate at Upcoming CDMO Live 2025 Conference
WuXi Biologics Receives CDMO Leadership Awards for Eighth Consecutive Year
Scinai to Connect with Investors, Showcase its Innovative I&I pipeline and its Boutique cGMP Biologics CDMO during BIO-Europe Spring 2025
Humanetics Selects Lifecore Biomedical to Deliver CDMO Services Supporting Development of BIO 300 for the Prevention of Acute Radiation Syndrome
The Schall Law Firm Invites Shareholders With Losses In Avid Bioservices, Inc. To Join A Securities Fraud Investigation
An Investigation Has Been Launched Into Avid Bioservices, Inc. For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm
The Schall Law Firm Invites Shareholders With Losses In Avid Bioservices, Inc. To Join A Securities Fraud Investigation
An Investigation Has Been Launched Into Avid Bioservices, Inc. For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm
The Schall Law Firm Invites Shareholders With Losses In Avid Bioservices, Inc. To Join A Securities Fraud Investigation
Avid Bioservices, Inc. Is Being Investigated For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm
The Schall Law Firm Invites Shareholders With Losses In Avid Bioservices, Inc. To Join A Securities Fraud Investigation
Avid Bioservices, Inc. Is Being Investigated For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm